Although combined administration of EPO and G-CSF represents a promising therapeutic strategy for stroke patients, most studies have focused on peripheral efficacy for the treatment of myelodysplastic syndromes [34,35,36,37]. This evidence concerns the gene CSF3 and myelodysplastic syndrome.